Hans Skovgaard Poulsen, MD, DMSc

Title: Head of Laboratory
Email: hans.skovgaard.poulsen@rh.regionh.dk
Phone: (+45) 35 45 63 03
Fax: (+45) 35 45 63 01

Date of Birth:

June 23rd. 1949

Current Position:

Associate Research professor, Chief Physician and Head of Section for Neuro-Oncology and Department of Radiation Biology

Education:

1978: MD, University of Aarhus, Denmark
1981-82: Senior Research Fellow in Pathology and Oncology, Columbia Presbyterian Hospital,
College of Physician and Surgeons, New York, USA
1984: Doctoral Thesis (PhD; Dr.Med.Sci.), University of Aarhus, Denmark
1988: Specialist in Oncology and Radiotherapy

Clinical Responsibilities:

Neuro-oncology (Head),Member of the team including GU cancer, sarcoma and tumors in children

Research responsibilities

Present research area: Lung cancer, brain tumors and growth factor receptor studies, with the principal aim to generate more insight into the malignant phenotype, and second aim to extend that knowledge to patient material in terms of testing possible prognostic factors, as well as suggesting new translational treatment modalities; targeting gene therapy alone or in combination with already used modalities.
The laboratory employs 13 people, 2 senior research scientists, 1 associated research assistant, 4 Ph.D. students, 2 master student, 2 technicians, 1 research nurse and 1 student worker. The laboratories have mainly been financed by competitive money from The Danish Medical Research Council, The Danish Cancer Society, University of Copenhagen, Rigshospitalet and several private foundations.
Supervision experiences: Mentor (2) and co-mentor (1) for doctoral theses; 16 Ph.D. Studies, 14 Approved, the rest in progress. In addition several student projects have been supervised. Referee for a number of international scientific journals.
Initiated and was head of the Receptor Laboratory, The Danish Cancer Society, Aarhus from 1980 to 1989. This laboratory developed new histological methods for oestrogen receptor assays and was one of 3-reference laboratory in Denmark. Initiated and is head of Department of Radiation Biology, Finsen Centre since 1993.

Evaluation of 14 PhD thesis and 11 Doctor thesis at the University Of Copenhagen, Aarhus, Odense, Lund, Bergen and the University of Dublin.

Other:
 

Teaching experience:

Associate professor, University of Copenhagen; human biology and oncology

Awards:

1976: Gold medal for Prize paper in Oncology, University of Aarhus,
1986: ESTRO travelling award
1998: Kaj Bunch-Jensen and Allis Bunch-Jensen’s award for Cancer Research
2008: The honouree award of the Danish Society for Cancer Research

Publications:

Prize paper in Oncology:                                                                                                        Poulsen HS: Prisopgave i radioterapi: Tildelt Aarhus Universitets guldmedalje: Der ønskes en undersøgelse af en in vitro metode til påvisning af humane mammacancer cellers hormonfølsomhed. Undersøgelsen skal baseres på litteraturstudier og egen metodik. AarhusUniversitet 1976, pp 1-103.

Doctoral thesis:                                                                                                                     Poulsen HS: In vitro tests and hormonal treatment of breast cancer. Disputats, Aarhus: Eget forlag 1984, pp 1-89. (Doctoral thesis).

154 original articles in scientific journals with peer-review
5 submitted papers to scientific journals with peer-review
9 original articles in journals without peer-review
8 book chapters
3 Patents

Articles

1. Poulsen HS: Demonstration of hormonal sensitivity in gynaecomastic tissue by
thymidine incorporation in vitro.
Acta path microbiol scand (section A), 85: 19-24, 1977.

2. Overgaard J, Poulsen HS: Brief Communication: Effect of hyperthermia and
environmental acidity on the proteolytic activity in murine ascites tumor cells.
J Natl Cancer Inst, 58: 1159-1161, 1977.

3. Poulsen HS: Absence of association between oestrogen-receptor content and in vitro
oestrogen sensitivity in human breast cancer.
Acta path microbiol scand (section A), 86: 169-172, 1978.

4. Nielsen HE, Poulsen HS, Olsen KJ, Gadeberg CC, Schultz H: Bone mineral
content and estrogen receptors in patients with breast cancer.
Europ. J. Cancer, 15: 703-707, 1979.

5. Poulsen HS, Schultz H, Bichel P: Oestrogen-receptor deter¬minations on fine-needle
aspirations from malignant tumours of the breast.
Europ J. Cancer, 15: 1431-1438, 1979.

6. Mørch-Jørgensen L, Poulsen HS, Larsson L-I: Formaldehyde-Fluorescami¬ne-
induced fluorescence of mammary carcinoma cells. Lack of concordan¬ce with occurence of
Oestrogen-binding proteins.
Virchows Arch B Cell Path, 30; 281-287, 1979.

7. Poulsen HS, Schultz HP, Hansen ES: Østrogen receptorbestem¬melse på malignt
humant mammavæv. Hvorledes undgås falsk negative resultater?
Ugeskr. Læg, 143: 192-194, 1981.

8. Poulsen HS: Oestrogen Receptor Assay-Limitation of the Method.
Europ. J. Cancer 17: 495-501, 1981.

9. Poulsen HS, Jensen J, Hermansen C: Human breast cancer: Hetero¬geneity of
estrogen binding sites.
Cancer, 48: 1791-1793, 1981.

10. Poulsen HS, Frederiksen P: Glucose-6-phosphate dehydroge¬nase activity in human
breast cancer. Lack of association with estrogen receptor content.
Acta path. microbiol scand. (section A), 89: 263-270, 1981.

11. Poulsen HS, Bichel P, Andersen J: Short-term culture of human breast cancer: In
vitro effects of hormones related to patient response.
Br J Cancer, 46: 67-74, 1982.

12. Bichel P, Poulsen HS, Andersen J: Estrogen receptor content and ploidy of human
mammary carcinoma.
Cancer, 50: 1771 - 1774, 1982.

13. Poulsen HS, L. Ozzello L, Andersen J: Oestrogen receptors in human breast cancer.
Problems of correlation with histopathological features.
Virchows Arch ( Pathol Anat ), 397: 103-108, 1982.

14. Poulsen HS: Estrogen receptors in human breast cancer. Comparative features of the
hydroxylapatite- and Dextran-coated charcoal assay.
Eur J Cancer Clin Oncol, 18: 1075-1079, 1982.

15. Poulsen HS: In vitro tests and hormonal treatment of breast cancer.
Progress in Surgical Pathology, pp 37-65., 1983.

16. Hermansen C, Poulsen HS, Jensen J, Langfeldt JB, Steenskov V, Frederiksen P,
Jensen OM: Palpable breast tumours: "Triple diagnosis" and operative strategy, Results of a
prospective study.
Acta Chir Scand, 150: 625-628, 1984.

17. Poulsen HS, Bukh A, Rytter L, Thomsen K, Ørntoft T, Andersen HU,
Møller NPH, Brünner N: Oestrogen receptor assay. False positive analysis?
Acta Radiologica Oncology, 23: 109-117, 1984.

18. Jacobsen A, Poulsen HS, Madsen EL, Petersen SE, Hansen HS: Ploidy
level of human breast carcinoma. Relation to histopathologic features and hormone receptor content.
Acta Radiologica Oncology, 23: 103-107, 1984.

19. Thorpe SM, Olsen K, Pedersen KO, Poulsen HS, Rose C: Quality control of
estrogen and progesterone receptor analyses in Denmark.
Res Results Cancer Res, 91: 91-93, 1984.

20. Poulsen HS, Ozzello L, King WJ, Greene GL: The use of monoclonal antibodies
to estrogen receptors (ER) for immunoperoxida¬se detection of ER in paraffin sections of human
breast cancer tissue.
J Histochem Cyto¬chem, 33: 87-92, 1985.

21. Ørntoft TF, Mors NPO, Eriksen G, Jacobsen NO, Poulsen HS: Comparative
immunoperoxidase demonstration of T-antigens in human colorectal carcinomas and
morphologically abnormal mucosa.
Cancer Res, 45: 447-452, 1985.

22. Brünner N, Spang-Thomsen M, Poulsen HS , Engelholm SA, Nielsen A, Vindeløv L:
Endocrine sensitivity of the receptor-positive T61 human breast carcinoma serially
grown in nude mice.
Int J Cancer, 35: 59-64, 1985.

23. Brünner N, Bastert GB, Poulsen HS, Spang-Thomsen M, Engelholm SA,
Vindeløv L, Nielsen A, Tommerup N, Elling F: Characterization of the T61 human
breast carcinoma established in nude mice.
Eur J Cancer Clin Oncol, 21: 833-843, 1985.

24. Nielsen HE, Saksø P, Poulsen HS, Gadeberg CC: Bone mineral content and
estrogen receptors in women with breast tumors.
Acta Radiologica Oncology, 24: 247-251, 1985.

25. Poulsen HS, Hermansen C, Andersen JA, Andersen HU, Jensen J:
Gynecomasty: Estrogen and androgen receptors. A clinical-pathological inves¬tigation.
Acta path. microbiol. immunol. scand. (section A), 93: 229-233, 1985.

26. Nielsen NSM, Poulsen HS: Relation between mammagraphic findings and
hormonal receptor content in breast cancer.
Am J Roentgenology, 145: 501-504, 1985.

27. Andersen J, Ørntoft TF, Poulsen HS: Semiquantitative oestrogen receptor assay in
formalin-fixed paraffin sections of human breast cancer tissue using monoclonal
antibodies.
Br J Cancer, 53: 691-694, 1986.

28. Rose C, Kamby C, Mouridsen HT, Bastholt L, Brincker H, Poulsen HS, Andersen AP,
Loft H, Dombernowsky P, Andersen KW: Com¬bined endocrine treatment of
postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs.
tamoxifen plus aminoglutethimide and hydrocortisone.
Breast Cancer Res Treat, 7: 45-50, 1986.

29. Hermansen C, Poulsen HS , Jensen J, Langfeldt B, Steenskov V, Frederiksen P,
Jensen OM: Diagnostic Reliability of Combined Physical Examinat¬ion, Mammography and
Fine-Needle Puncture ("Triple Test") in Breast Tumors. A Prospective Study.
Cancer, 60: 1866-1871, 1987.

30. Andersen J, Andersen JA, Ørntoft TF, Poulsen HS: Gynecomastia:
Immunohistochemical demonstration of estrogen receptors.
Acta path. microbiol. immunol. scand.( Section A ), 95: 263-267, 1987.

31. Andersen J, Poulsen HS: Immunohistochemical analysis of estrogen receptors (ER)
using formalin-fixed paraffin-embedded breast cancer tissue: Correlation with clinical endocrine
response.
J. steroid Biochem, 30: 337-339, 1988.

32. Bentzen SM , Poulsen HS Kaae S, Jensen OM, Johansen H, Mouridsen HT, Daugaard S,
Arnoldi C: Prognostic factors in osteosarcomas. A regression analysis.
Cancer, 62: 194-202, 1988.

33. Jacobsen A, Hansen V, Poulsen HS: DNA profile and steroid receptor content of human
ovarian cancer.
Eur J Gynaec Oncol, 6: 461-463, 1988.

34. Andersen J, Bentzen SM, Poulsen HS: Relationship between radio¬ligand binding assay,
immunoenzyme assay and immunohistoche¬mical assay for estrogen receptors in
human breast cancer and association with tumor differen¬tiation.
Eur J Cancer Clin Oncol, 24: 377-384, 1988.

35. Bukh A, Agua MT, Krarup N, Poulsen HS, Nordentoft AM, Møller NP:
A prospective study of circulating immune complexes in patients with breast cancer.
Int. J Cancer, marts 15; 41,364-70, 1988.

36. Thorpe SM, Poulsen HS, Pedersen KO, Rose C: Impact of standardization of estrogen and
progesterone receptor assays of breast cancer biopsies in Denmark.
Eur J Cancer Clin Oncol, 24: 1263-1269, 1988.

37. Andersen J, Ørntoft TF, Poulsen HS: Immunohistoche¬mical demonstration of estrogen
receptors (ER) in formalin-fixed, paraffin-embedded human breast cancer tissue by
use of a monoclonal antibody to ER1.
J histochem Cytochem, 36: 1553-1560, 1988.

38. Andersen J, Poulsen HS: Relationship between estrogen receptor status in the primary tumor
and its regional and distant metastases. An immuno¬histochemical study in human
breast cancer.
Acta Oncologica, 27: 761-765, 1988.

39. Thorpe SM, Poulsen HS, Pedersen KO, Rose C: Quality control of receptor analyses of
breast cancer tissue in Denmark.
Acta Oncologica, 27: 621 - 625, 1988.

40. Andersen J, Skovbon H, Poulsen HS: Immunocytochemical deter¬mination of the estrogen
regulated protein Mr 24.000 in primary breast cancer and response to endocrine
therapy.
Eur J Cancer Clin Oncol, 25: 641-643, 1989.

41. Scopsi L, Balslev E, Brünner N, Poulsen HS, Andersen J, Rank F, Larsson L-I:
Immunoreactive opioid peptides in human breast cancer.
American J Pathol, 134, 2: 473-479, 1989.

42. Andersen J, Poulsen HS: Immunohistochemical Estrogen Receptor Determination in Paraffin
Embedded Tissue. Prediction of response to hormonal treatment in advanced breast
cancer.
Cancer, 64: 1901 - 1908, 1989.

43. Jørgensen LJ, Poulsen HS, Nordentoft AM, Jensen OM, Sneppen O: Sarcoma
Synoviale.
Ugeskr Læger, 151: 1325-1328, 1989.

44. Nielsen OS, Poulsen HS: Knoglemetastaser.
Ugeskr Læger, 151: 362-365, 1989.

45. Poulsen HS, Nielsen OS, Klee M, Rørth M: Palliative irr¬adiation of Bone
Metastases.
Cancer Treat Review, 16: 41-48, 1989.

46. Rørth M, Poulsen HS: Behandling af Kræftsygdomme.
Ugeskr Læger, 151: 325-330, 1989.

47. Damstrup L, Rørth M, Poulsen HS: Growth factors and growth factor receptors in human malignancies, with special reference to human lung cancer: a review.
Lung Cancer, 5: 49-68, 1989.

48. Poulsen HS: Cancer cell cultures and their clinical application.
Reviews Endocrine-Related Cancer, 33: 17-22, 1989.

49. Krarup-Hansen A, Poulsen HS: Extra-visceral soft tissue sarcomas in adults:
local treatment, with special reference to irradiation.
Cancer Treat Reviews, 16: 221-246, 1989.

50. Andersen J, Thorpe SM, King WJ, Rose C, Christensen I, Rasmus¬sen BB, Thorpe SM,
Poulsen HS: The prognostic value of immunohistochemical estrogen receptor analysis in
paraffin-embedded and frozen sections versus that of Steroid-binding assays.
Eur J Cancer Clin Oncol, 26: 442-449, 1990.

51. Mouridsen HT, Dombernowsky P, Jensen OM, Johansen H, Lund B, Nordentoft A,, Poulsen
HS,Schiødt T, Sneppen O: Sarkom Behandling i Danmark.
Ugeskr Læger, 152: 989-992, 1990.

52. Andersen J, Thorpe SM, Rose C, Christensen I, Rasmussen BB, Poulsen HS : Estrogen
receptor in primary breast cancer estimated in paraffin-embedded tissue. A study of its
usefulness compared to dextran-coated charcoal assay.
Acta Oncologica, 30: 685-690, 1991.

53. Becker U, Andersen J, Poulsen HS, Burcharth F, Gluud C, Horn T:
Enzyme immunoassay of oestrogen receptors in needle bi¬o¬p¬s¬ies from human liver.
Liver, 11: 292-299, 1991.

54. Hippe E, Jønsson V, von der Maase H, Mathiesen JC, Poulsen HS: Homoeostatic
response criteria for cancer therapy.
Eur J Cancer, 27: 1715-1716, 1991.

55. Nørgaard P, Poulsen HS: Glucocorticoid receptors in human malig¬nan¬cies: A review.
Ann Oncol, 2: 541-557, 1991.

56. Nielsen NSM, Andersen J, Poulsen HS, Mathiessen O: Prediction of hormone
responsiveness by mammographic parenchymal pattern in advanced primary breast
cancer.
Breast Cancer Res Treat, 23: 219-222, 1992.

57. Damstrup L, Andersen J, Kufe DW, Hayes DF, Poulsen HS: Immunocyt-
ochemical determination of the Estrogen-regulated proteins Mr 24.000,Mr 52.000 and DF3
breast cancer associated antigen:Clinical value in advanced breast cancer and correlation with
estrogen receptor.
Ann Oncol, 3: 71-77, 1992.

58. Becker U, Andersen J, Poulsen HS, Horn T: Variation in hepatic estrogen receptor
concentrations in patients with liver disease: A mul¬tivariate analysis.
Scand J Gastroenterol, 27: 355-361, 1992.

59. Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS: Expression of the
Epidermal Growth Factor Receptor in Human Small Cell Lung Cancer Cell Lines.
Cancer Res 52: 3089- 3093, 1992.

60. Nørgaard P, Damstrup L, Spang-Thomsen M, Poulsen HS: Trans¬forming growth
factor- b. En potent multifunktionel vækstfaktor for normale og maligne celler.
Ugeskr Læger, 154: 3494-3498, 1992.

61. Becker U, Andersen J, Poulsen HS,Horn T:
Hepatic cytosolic oestrogen receptors in patients with liver disease.
J Intern Med. Feb; 233(2), 165-72, 1993.

62. Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS: Expres¬sion of
transforming growth factor b (TGF b) receptors of TGF b 1, TGF b 2, and TGFb 3 in
human small cell lung cancer cell lines.
Br J Cancer, 67: 1015-1021, 1993.

63. Nørgaard P, Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS: Growth
suppresion by transforming growth factor b of human small cell lung cancer cell lines is
associated with expression of type II receptor.
Br J Cancer, 69: 802 - 808, 1994.

64. Damstrup L, Poulsen HS: Review of the curative role of radiotherapy in the treatment
of non - small cell lung cancer.
Lung Cancer, 11: 153- 178, 1994.

65. Bouchelouche PN, Berild D, Nielsen OH, Elmgreen J, Poulsen HS :
Leukotriene B4 receptor levels and intracellular calcium, signalling in polymorpho-
nuclear leukocytes from patients with Chron’s disease.
Eur J Gatroent Hepatol, 7: 349 - 356, 1995.

66. Nørgaard P, Hougaard S, Spang-Thomsen M, Poulsen HS: Transforming Growth
Factor b and Cancer.
Cancer Treat Reviews, 21: 367 - 403, 1995.

67. Poulsen HS, Sørensen JB: Management of patients with Lung Cancer.
Oncology in Practice, 1995.

68. Nørgaard P, Spang-Thomsen M, Poulsen HS: Expression and autoregulation of transforming
growth factor b receptor mRNA in small- cell lung cancer cell lines.
Br J Cancer, 73: 1037 - 1043, 1996.

69. Nørgaard P, Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS: Acquired
TGF -b1 sensitivity and TGF-b1 expression in cell lines established from a single small cell lung
cancer patient during clinical progression.
Lung Cancer, 14: 63 - 73, 1996.

70. Kristensen CA, Jensen PB, Poulsen HS, Hansen HH: Small Cell Lung Cancer:
Biological and therapeutic aspects.
Critical Review in Oncology/ Hæmatol, 22: 27 - 60, 1996.

71. Pedersen AN, Højer-Hansen G, Brünner N, Clark GM, Larsen B, Poulsen HS, Danø K,
Stephens RW: The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
J Immun Methods, 203: 55 - 65, 1997.

72. Krarup M, Poulsen HS, Spang-Thomsen M: Cellular Radiosensitivity of small-cell
lung cancer cell lines.
Int J Radiation Oncology Biol Phys, 38: 191 - 196, 1997.

73. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS: Epidermal
growth factor receptor (EGFR) and EGFR mutations, function and possible role in
clinical trials.
Ann Oncol, 8: 1197 - 1206, 1997.

74. Helin K, Holm K, Niebuhr A, Eiberg H, Tommerup N, Hougaard S, Poulsen HS,
Spang-Thomsen M, Nørgaard P: Loss of the retinoblastoma protein - related p130 protein in
small cell lung carcinoma.
Proc Natl Acad Sci, 94: 6933 - 6938, 1997.

75. Damstrup L, Voldborg BR, Spang-Thomsen M, Brunner N, H. Poulsen HS: In vitro
invasion of small - cell lung cancer cell lines correlates with expression of epidermal growth
factor receptor.
Br J Cancer, 78: 631 - 640, 1998.

76. Hougaard S, Krarup M, Nørgaard P, Damstrup L, Spang-Thomsen M, Poulsen HS:
High value of the radiobiological parameter Dq correlates to expression of the transforming
growth factor b type II receptor in a panel of small cell lung cancer cell lines.
Lung Cancer, 20, 65 - 69, 1998.

77. Lassen U, Andersen P, Daugaard G, Holm S, Jensen M, Svarre C, Poulsen HS, Paulson OB:
Metabolic and hemodynamic evaluation of brain metastases from small cell lung cancer with
positron emission topography.
Clin. Cancer Res., 501-3, 1998.

78. Lund EL, Spang-Thomsen M, Poulsen HS, Kristjansen PEG:
Tumor angiogenesis - a new therapeutic target in gliomas.
Acta Neu Scand, 97: 52 - 62, 1998.

79. Damstrup L, Kuwada SK, Dempsey PJ, Brown CL, Hawkey CJ, Poulsen HS,
Wiley HS, Coffey RJ: Amphiregulin acts as an autocrine growth factor in two human
polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis.
Br J Cancer, 80: 1012 – 1019, 1999.

80. Nørgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE,
Oliff A, Coffey RJ, Poulsen HS, Moses HL: Treatment with farnesyl-protein transferase
inhibitor induces regression of mammary tumors in transforming growth factor (TGF) apha and
TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
Clin Cancer Res, 5: 35 - 42, 1999.

81. Hougaard S, Nørgaard P, Abrahamsen N, Moses HL, Spang-Thomsen M, Poulsen HS:
Inactivation of the transforming growth factor b type II receptor in human small cell lung
cancer cell lines.
Br J Cancer, 79: 1005 - 1011, 1999.

82. Lassen U, Kristjansen PEG, Wagner Aa, Kosteljanetz M, Poulsen HS: Treatment of newly
diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by
radiotherapy. A phase II study.
J NeuroOncol, 43: 161 – 166, 1999.

83. Schmiegelow M, Weber L, Lassen S, Poulsen HS , Hertz H, Müller J:
Dosimetry and growth hormone deficiency following cranial irradiation of childhood brain tumors.
Med Pediatr Oncol, 33: 564 – 571, 1999.

84. Law BK, Nørgaard P, Gnudi L, Kahn BB, Poulsen HS, Moses HL: Inhibition of DNA
Synthesis by a Farnesyltransferase Inhibitor Involves Inhibition of the p70 (s6k) Pathway
J Biol Chem, 19: 4743 - 4748, 1999.

85. Nørgaard P, Law BK, Poulsen HS, Moses HL: Farnesyltransferase inhibitor-induced
regression of mammary tumors in TGF alpha and TGF alpha/neu transgenic mice correlates
with inhibition of map kinase and p70s6 kinase phosphorylation.
Ann N Y Acad Sci, 886: 265-8, 1999.

86. Frederiksen KS, Petri A, Abrahamsen N, Damstrup L, Poulsen HS: Gene therapy for Lung
Cancer.
Lung Cancer, 23: 191- 107, 1999.

87. Frederiksen KS, Abrahamsen N, Cristiano RJ, Damstrup L, Poulsen HS: Gene
delivery by an epidermal growth factor/ DNA polyplex to small cell lung cancer cell lines
expressing low levels of epidermal growth factor receptor.
Cancer Gene Ther, 7: 262 – 268, 2000.

88. Schmiegelow M, Lassen S, Poulsen HS, Feldt-Rasmussen U, Schmiegelow K., Hertz H,
Müller JR: Biological Effective Dose-GH-Deficiency. Cranial radiotherapy of childhood brain
tumors: Growth hormone deficiency and the relation to the biological effective dose of irradiation in a large population based study
Clin Endocrinol (Oxf);53(2): 191-7, 2000.

89. Schmiegelow M, Lassen S, Poulsen HS, Feldt-Rasmussen U, Schmiegelow K, Hertz H,
Müller JR:
Growth Hormone Response to a Growth Hormone Releasing Hormone Stimulation Test in a
Population Based Study Following Irradiation of Childhood Brain Tumours.
Horm Res, 54(2): 53-59, 2000.

90. Pedersen MW, Thykjær T, Ørntoft TF, Damstrup L, Poulsen HS: Profile of differentially expressed genes mediated by the Type III Epidermal Growth Factor Receptor mutation in small cell lung cancer cell line.
Br J Cancer; 85( 8 ): 1211 - 1218, 2001.

91. Schmiegelow M, Lassen S, Poulsen HS, Schmiegelow K, Hertz H, Andersson AM, Skakkebæk NE, Müller J: Gonodal status in male survivors following childhood brain tumors.
J Clin Endocrin Metab, 86: 2446 – 2452, 2001.

92. Wurtzen PA, Pedersen L, Poulsen HS, Claesson MH: Specific killing of P53 mutated tumor cell lines by cross-reactive huam HLA-A2-restricted P53-specific CTL line.
Int J Cancer, 93: 855-861, 2001.

93. Pedersen MW, Meltorn M, Poulsen HS: The Type III EGF receptor growth factor mutation. Ann Oncol, 12: 745 – 760, 2001.

94. Damstrup L, Pedersen MW, Bastholm L, Elling F, Poulsen HS: Epidermal Growth Factor
Receptor Mutation Type III transfected into small cell lung cancer cell line is predominantly
localized at the cell surface and enhance tumorigeneity.
Int J Cancer, 97: 7 –14, 2002.

95. Mortensen S, Sørensen SB, Poulsen HS: Genterapi og cancer.
Ugskrf Læger, 164: 1785 – 1790, 2002.

96. Pedersen MW, Poulsen HS: Epidermal Growth Factor Receptor in Cancer Therapy.
Science & Medicine, august: 206- 217, 2002.

97. Schmiegelow M, Feldt-Rasmussen U, Rasmussen ÅK, Hertz H, Poulsen HS, Müller J: Thyroid function in Childhood brain tumor. A population based study of Thyroid function after Radiotherapy and Chemotherapy for a Childhood brain tumor.
J Clin Endocrinol Metab, 88(1): 136-40, 2003.

98. Hansen LRT, Lundin C, Helleday T, Poulsen HS, Petersen LN, Spang-Thomsen M: DNA repair rate and etoposide resistance in two tumor cell subpopulations derived from a single human small cell lung cancer.
Lung Cancer, 40(2): 157-64, 2003.

99. Pedersen N, Mortensen S, Sørensen SB, Pedersen MW, Rieneck K, Bovin LF, Poulsen HS: Transcriptional gene expression profiling of small cell lung cancer cells.
Cancer Res 63(8):1943-53. 2003.

100. Nielsen KL, Allen MR, Bloomfield SA, Andersen TL, Chen X, Xu T, Poulsen HS, Young MF, Heegaard M: Biglycan Deficiency interferes with overiectomy-induced bone loss.
J Bone Miner Res, 18(12): 2152-2158, 2003.

101. Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK, Lange M, Poulsen HS, Müller J: Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients treated with Cranial Radiotherapy for a Childhood Brain Tumor.
J Clin Endocrinol Metab, 88(7): 3149-54, 2003.

102. Heydenreich AV, Westmeier R, Pedersen N, Poulsen HS, Kristensen HG: Preparation and purification of cationic nanospheres – effects on particle size, physical stability and cell toxicity.
Int J Pharm, 254: 83-87, 2003.

103. Pedersen N, Poulsen HS: New drug modalities for treatment of lung cancer.
Review Series Oncology, 2/2003: 2-6, 2003.

104. Pedersen MW, Tkach V, Pedersen N, Berezin V and Poulsen HS: Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases cell motility.
Int J Cancer, 108: 643-653, 2004.

105. Christensen HC, Schüz J, Kosteljanetz M, Poulsen HS, Thomsen J, Johansen C: Cellular telephone use and risk for acoustic neurinoma.
Am J Epidemiology, 159(3): 277-83, 2004.

106. Pedersen MW, Pedersen N, Damstrup L, Villingshøj M, Sønder SU, Rieneck K, Bovin LF, Spang-Thomsen M, Poulsen HS: Analysis of the epidermal growth factor receptor specific transcriptome: effect of expression level and an activating mutation.
J Cell Biocem, 96(2): 412-427, 2005.

107. Poulsen TT, Pedersen N, Perin MS, Celia K, Hansen CK, Poulsen HS: Specific sensitivity
of small cell lung cancer cell lines to the snake venom toxin taipoxin.
Lung Cancer, 50(3): 329-337, 2005.

108. Christensen HC, Schüz J, Kosteljanetz M, Poulsen HS, Boice J, McLaughlin, Johansen C:
Cellular telephone and risk for brain tumors. A population-based, incident case-control study.
Neurology, 64(7): 1189-95, 2005.

109. Pedersen MW, Pedersen N, Ottesen LH, Poulsen HS: Differential response to gefinitib of cells
expressing normal EGFR and the mutant EGFRvIII.
Br J Cancer, 93: 915-923, 2005.

110. Poulsen TT, Pedersen N, Poulsen HS: Replacement and suicide gene therapy for targeted treatment of lung cancer.
Clin Lung Cancer, 6: 227-236, 2005.

111. Pedersen N, Hansen SE, Heydenreich AV, Kristensen HG. and Poulsen HS: Solid lipid
nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands.
Eur J Pharm Biopharm, 62:155-162, 2006.

112. Pedersen N, Pedersen MW, Lan MS, Breslin MB, Poulsen HS: The insulinoma-associated 1:
a novel promoter for targeted cancer gene therapy for small cell lung cancer.
Cancer Gene Ther, 13: 375-384, 2006.

113. Vestergaard J, Pedersen MW, Pedersen N, Ensinger C, Tümer Z, Tommerup N, Poulsen HS, Larsen LA: Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro.
Lung Cancer, 52:281-290, 2006.

114. Andersen PB, Blinkenberg M, Lassen U, Kosteljanetz M, Wagner A, Poulsen HS, Sørensen PS, Paulson OB: A prospective PET study of patients with glioblastoma multiforme.
Acta Neurol Scand, 113(6): 412-8, 2006.

115. Pedersen MW, Poulsen HS: Mutationer i EGF receptoren: struktur og tumorbiologisk relevans. Ugeskr Læger, 168:2 354-2361, 2006.

116. Poulsen HS: Gliomer hos voksne: Primær ikke kirurgisk behandling.
Ugeskr Læger, 168: 4082-5, 2006.

117. Spindler K-LG, Olsen DA, Nielsen JN, Brandslund I, Poulsen HS, Villingshøj M, Jakobsen A:
Lack of the Type III Epidermal Growth Factor Receptor Mutation in Colorectal Cancer.
Anticancer Res, 26 (6C): 4889-93, 2006.

118. Pedersen N, Poulsen TT, Poulsen HS: Cre/loxP recombination vectors for promoter studies.
Electron J Biotechol, 10:315-321, 2007.

119. Larsen AB, Pedersen MW, Stockhausen M, Grandal MV, van Deurs B, Poulsen HS: Activation of the EGFR target gene EphA2 inhibits EGF-induced cancer cell motility.
Molecular Cancer Research, 5(3): 283-293, 2007.

120. Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B, Poulsen HS: EGFRvIII escapes downregulation due to impaired internalization and sorting to lysosomes.
Carcinogenesis, 28(7): 1408-17, 2007.

121. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS: Mechanisms for oncogenic activation of the epidermal growth factor receptor.
Cellular Signalling, 19 (10) 2013-23, 2007.

122. Andersen P, Pedersen MW, Woetmann A, Stockhausen MT, Ødum N, Poulsen HS: EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells.
Int. J. Cancer, Jan 15; 122(2): 342-9, 2008.

123. Poulsen TT, Pedersen N, Poulsen HS: A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells.
Cancer Gene Therapy 15: 563-575, 2008.

124. Hansen CL, Hansen PR, Pedersen N, Poulsen HS, Gillings N, Kjær A: Identification of amino acid residues in PEPHC1 important for binding to the tumor-specific receptor EGFRvlll.
Chem Biol Drug Des. 72(4): 273-82, 2008.

125. Poulsen TT, Naizhen X, Poulsen HS, Linnoila IR: Acute damage by naphthalene triggers expression of the neuroendocrine marker PGP9.5 in airway epithelial cells.
Toxicol Lett 181: 67-74, 2008.

126. Poulsen HS, Grunnet K, Sørensen M, Olsen P, Hasselbalch B, Kosteljanetz M, Lassen U: Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
Acta Oncologica. 48(1): 52-8, 2009.

127. Andersen P, Villingshøj M, Poulsen HS, Stockhausen MT: Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells.
Cancer Invest 27 (2): 178-83, 2009.

128. Denholt CL, Hansen PR, Pedersen N, Poulsen HS, Gillings N, Kjær A: Identification of
novel receptor binding ligands for EFGRvIII using a mixture-based synthetic
combinatorial library.
Biopolymers. 91(3): 201-206, 2009.

129. Christensen CL, Zandi R, Gjetting T, Cramer F, Poulsen HS:
Specifically targeted gene therapy for small cell lung cancer.
Expert Review of Anticancer therapy. 9(4): 437-52, 2009.

130. Stockhausen MT, Kristoffersen K, Poulsen HS: The Functional role of Notch
signaling in human gliomas.
Neuro Oncol. Feb; 12(2): 199-211, 2010.

131. Sørensen M, Gaziel TB, Hasselbalch B, Poulsen HS, Lassen U: Severe skin
lesions in patients with glioblastoma multiforme treated with a combination of
cetuximab, bevacizumab and irinotecan.
European Journal of Clinical & Medical Oncology 1(2): 1-3, 2009.

132. Larsen AB, Stockhausen M, and Poulsen HS: Cell adhesion and EGFR activation regulate EphA2 expression in cancer.
Cellular Signalling 22:636-644, 2010.

133. Kosteljanetz M, Poulsen HS: Kemoterapi imprægnerede wafers i
behandlingen af maligne gliomer i hjernen. En gennemgang af et Cochrane Review.
Ugeskrift for Læger, Jan 18; 172(3): 214-217, 2010.

134. Christensen CL, Gjetting T, Poulsen TT, Cramer F, Roth JA, Poulsen HS: Targeted cytosine deaminase-uracil phosphoribosyl transferase induces SCLC specific cytotoxicity and tumor growth delay.
Clin Cancer Res; April 15; 16(8):2308-19, 2010.

135. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M,
Broholm H, Stockhausen MT, Poulsen HS: Cetuximab, Bevacizumab and
Irinotecan for Patients with Primary Glioblastoma and Progression after
Radiation Therapy and Temozolomide: A Phase II trial.
Neuro Oncol. May; 12(5): 508-16, 2010.

136. Hasselbalch B, Lassen U, Poulsen HS, Stockhausen MT: Cetuximab is insufficient in inhibiting cell growth due to persistent EGFR downstream signalling.
Cancer Investigation, May 26. 2010.

137. Gjetting T, Arildsen NS, Christensen CL, Poulsen TT, Roth JA, Handlos VN, Poulsen HS: In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP/cholesterol-mediated gene transfection.
Int. J. Nanomedicine.: Aug.9; 5:371-83, 2010.

138. Bartkova J, Hamerlik P, Stockhausen MT, Ehrmann J, Laursen H, Katita O, Kolar Z, Poulsen HS, Broholm H, Lukas J, Bartek J: Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signaling in human gliomas.
Oncogene.: Sep 9;29(36):5095-102, 2010.

139. Hasselbalch B, Eriksen JG, Broholm H, Christensen IJ, Grunnet K, Horsman MR, Poulsen HS, Stockhausen MT, Lassen U: Prospective evaluation of angiogenic, hypoxic and EGFR related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.
APMIS, Aug; 118(8): 585-94, 2010.

140. Olszewski U, Poulsen TT, Ulsberger E, Poulsen HS, Geissler K, Hamilton G: Invitro cytotoxity of combinations of dichloroacetate with anticancer platinum compounds.
Clinical Pharmacology: Advances and Applications: 2 1-7, 2010.

141. Madsen K, Poulsen HS: Needs for support in everyday life for next of kin to brain tumor patients: a systematic literature review.
European Journal of Cancer Care. Jan;20(1):33-43, 2011

142. Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS: Irinotecan and bevacizumab treatment of recurrence of Glioblastoma Multiforme.
Expert Opinion On Pharmacotherapy: Apr; 12(5): 825-33, 2011.

143. Denholt C, Binderup T, Stockhausen MT, Poulsen HS, Spang-Thomsen, Hansen PR, Gillings N, Kjær A: Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a Positron Emission Tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer.
Nuclear Medicine and Biology. May; 38(4): 509-15, 2011.

144. Zandi R, Selivanova G, Christensen CL, Willumsen BM, Poulsen HS:”PRIMA-1Met induces apoptosis in Small Cell Lung Cancer expressing mutant p53”.
Clin Cancer Research, May 1; 17(9): 2830-41, 2011.

145. Stockhausen MT, Broholm H, Villingshøj M, Kirchhoff M, Gerdes T, Kristoffersen K, Kosteljanetz M, Spang-Thomsen M, and Poulsen HS: Maintenance of EGFR and EGFRvIII expression in an in vivo and in vitro model of human glioblastoma multiforme.
Experimental Cell Research: Jul 1; 317(11): 1513-26, 2011.

146. Gjetting T, Andresen TL, Christensen CL, Poulsen TT, Cramer F, Poulsen HS : A simple protocol for preparation of a liposomal vesicle with encapsulated plasmid DNA that
mediate high accumulation and reporter gene activity in tumor tissue.
Results in Pharma Sciences 1: 49-56, 2011.

147. Henriksson R, Asklund T, Poulsen HS: Impact of therapy on quality of life, neurocognitive function and their correlates in Glioblastoma Multiforme.
J. Neurooncol. : Sep; 104(3): 639-46, 2011.

148. Zandi R, Xu K, Poulsen HS, Roth JA and Ji L: The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells.
Cancer Investigation, 29(10):683–691, 2011

149.Poulsen HS, Von der Maase H.: MiRNA ved glioblastomer - potentiale og begrænsninger. Ugeskr. Læger, Marts 5; 174(10): 628, 2012

150.Nedergaard MK, Hedegaard CJ, Poulsen HS: Targeting the Epidermal growth factor receptor in solid tumor malignancies. BioDrugs: Apr 1;26(2):83-99. 2012

151.Stockhausen MT, Kristoffersen K, Poulsen HS: Notch signaling and brain tumors. Adv Exp Med Biol.727:289-30, 2012

152. Zandi R, Xu K, Poulsen HS, Roth JA and Ji L: Overexpression of the novel tumor suppressor gene FUS1 suppresses the growth of small cell Lung cancer cells. Clinical and Experimental Pathology. In press.

153. Møller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, Poulsen HS, Lassen U: A phase II trial with bevacizumab and irinotecanfor patients with primary brain tumors and
progression after standard therapy. Acta Oncologica. In press. 

Articles submitted

1. Denholt CL, Kuhnast B, Hinnen F, Pedersen N, Poulsen HS, Dollé F, Hansen PR, Kjær A: Flourine-18 labelling studies of PEPHC1, a peptide specific towards EGFRvIII, and a number of truncated analogues. Submitted.

2. Larsen AB, Stockhausen MT, Grandal MV, Broholm H, Poulsen HS: EGFR and EphA2 interacts in cancer cells and localize together in vivo. Submitted.

3. Bondgaard ALRØ, Poulsen TT, Poulsen HS, Skov BG: Different Expression of EZH2, BMI1 and Ki67 in Low and High Grade Neuroendocrine Tumors of the Lung. Submitted.

4. Borghetti P, Eriksen JG, Horsman MR, Magrini SM, Poulsen HS Hasselbalch B: Has the quality of vessels a value in the treatment of Glioblastoma Multiforme? A study on the role of GLUT1 in neoangiogenesis. Submitted.

5. Christensen CL, Binderup T, Jonhbeck CB, Cramer F, Michaelsen SR, Kjær A, Poulsen HS: Adenoviral-mediated delivery of INSM1 promoter-driven YCD-YUPRT/5-FC therapy causes significant and sustained inhibition of SCLC tumor growth as assessed by PET/CT imaging. Submitted.

Articles without peer-review

1. Poulsen HS, Ozzello L, King WJ, Greene GL:
Immunocytochemistry of oestrogen receptors in human breast cancer. Reviews Endocrine-Rel Cancer 19: 21-26, 1986.

2. Brünner N, Spang-Thomsen M, Poulsen HS, Vindeløv L, Engelholm SA: Effect of tamoxifen on growth and cell kinetics of two human breast carcinomas grown in nude mice. Reviews Endocrine-Rel Cancer 19: 125-130, 1986.

3. Ørntoft T, Bendtsen L, Poulsen HS, Petersen SE, Wolf H, Pedersen S, Bolund L: Dual parameter flow cytometric measurement of DNA-content and lectin binding in human bladder tumors. In: Lectins, vol. V. TC Bøg-Hansen, E. van Driessche (eds). Berlin - New York. Walter de Gruyter & Co. pp. 545-550, 1986.

4. Brünner N, Spang-Thomsen M, Poulsen HS, Vindeløv L, Engelholm SA: Characterization of the T60 human breast carcinoma grown in nude mice: special reference to endocrine therapy studies. In: Immune-deficient Animals in Biochemical Research. Rygaard J, Spang-Thomsen M, Brünner N Græm N. Basel: Karger Publishing, pp. 234-241, 1987.

5. Poulsen HS, Rytter L, Brünner N, Ørntoft T, Andersen J, Spang-Thomsen M: Steroid receptor profile in human breast cancer grown in nude mice. In: Immune-deficient Animals in Biochemical Research. J. Rygaard, M. Spang-Thomsen, N. Brünner, N. Græm (eds). Basel, Karger Publishing, pp. 255-259, 1987.

6. Brünner N, Poulsen HS, Clarke R, Spang-Thomsen M: Effect of oophorectomy on estrogen and progesterone receptor concentrations in an ovarian-dependent and ovarian independent human breast cancer grown in nude mice. In: Wu B-q, Zheng J (eds): Immune-deficient Animals in Experimental Medicine. 6 th. Int. Workshop on Immune-deficient animals, Karger, Basel, pp: 196-201, 1989.

7. Damstrup L, Andersen J, Kufe DW, Hayes DF, Poulsen HS: Estrogen-regulated proteins in human breast cancer: Clinical value in advanced breast cancer and correlation with estrogen receptor. In: Recent advances in cellular and molecular biology, edited by Wegman,R.J. and Wegman,M.A., Leuven, Belgium: Peeters Press, p. 243-251, 1992.

8. Krarup M, Poulsen HS, Spang-Thomsen M: Expression of cell cycle regulating mRNA in small cell lung cancer xenografts. Folia Microbiologica 43: 501 - 503,1998.

9. Poulsen HS, Ulrichsen H. Kommentar: Når læger laver medicin.
Ugeskrift Læger 40: 5545 – 5546, 2001.

Book chapters

1. Poulsen HS: In vitro observations in relation to response, Chp.7.
In: Endocrine Management of Cancer 1: Biological bases. B. Stoll (ed). Basel: Karger Publishing 1988, pp. 72-83.

2. Olsen I, Poulsen HS, Kosteljanetz M: Værd at vide om hjernesvulster. Finsencenter, Rigshospitalet 1996, 1- 36.

3. Geisling PQ, Poulsen HS, Kosteljanetz M: Hjernesvulster. Kræftens Bekæmpelse, 1996, 1- 36.

4. Hougaard S, Nørgaard P, Poulsen HS: TGFb and lung cancer.
In: J.R. Benson: TGF- beta and Cancer. Landes Bioscience Publishers 1997.

5. Frederiksen KS, Petri A, Abrahamsen N, Poulsen HS: Gene therapy of Lung Cancer. In: F. Hirch: Lung Cancer, 1999.

6. Poulsen TT, Pappot H, Poulsen HS. Molecular Biology in Lung Cancer. IASLC Textbook on Lung Cancer, 2nd edition, edited by Hansen HH, Informa Healthcare, 2008.

7. Hasselbalch B, Lassen U, Poulsen HS.. Patients with Recurrent High-Grade Glioma. Therapy with Combination of Bevacizumab and Irinotecan. In: M.A. Hayat, Tumors of the central nervous system. Volume 2. Springer 2011, pp 289-301.

8. Stockhausen MT, Kristoffersen K, Poulsen HS. Notch Signaling and Brain Tumors. In: Reichrath J and Reichrath S. Notch Signaling in Embryology and Cancer. Landes Bioscience, and Springer, 2011.

Patents

1. Co- inventor of: Targeted gene therapy in small cell lung cancer. 2000-03-17 (Agent: Ploughmann, Vingtoft & Partners).

2. Co- inventor af: Oncology Drug Innovation. Receptorer og promotorer til genterapi. 2001-06-25 Patent PA 2001 00992 og 2002 (Agent: Høiberg Aps) Publication date 3. January 2003, Patent number WO03000928.

3. Co-inventor af: Insulinoma Associated-1 promoter-specific therapy of neuroendocrine tumors. 2005 (Agent: Taylor, Porter, Brooks & Phillips L.L.P).16

International reviews

1. Bunn P, Carbone D, Grim J, Harris C, Havemann K, Mabry M, Roth J, Saijo N, Poulsen HS, Stahel R, Takahashi T, Twentyman P. Fifth I.A.S.L.C. Lung Tumor Biology Workshop, August 13 - 17, 1996, Ermatingen, Switzerland. Commentary. Ann Oncology 8: 27 - 36, 1997.

2. Bunn P, Carbone D, Grim J, Harris C, Havemann K, Mabry M, Roth J, Saijo N, Poulsen HS, Stahel R, Takahashi T, Twentyman P. Fifth I.A.S.L.C. Lung Tumor Biology Workshop, August 13 - 17, 1996, Ermatingen, Switzerland. Commentary. Lung Cancer 16: 239 - 257, 1997